Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy

Neurology

Volumn 56, Issue 3, 2001, Pages 355-361

  Stingele, K ^a   Haas, J ^a   Zimmermann, T ^a   Stingele, R ^a   Hubsch Muller C ^a   Freitag, M ^a   Storch Hagenlocher, B ^a   Hartmann, M ^a   Wildemann, Brigitte ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR EVOLUTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0035852835     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.3.355     Document Type: Article

References (39)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
3. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
4. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
5. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
8. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
9. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
10. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine
11. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture
12. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
13. Resistance to antiretroviral compounds: Implications for the clinical management of HIV infection
14. HIV resistance and implications for therapy
15. Rapid turnover of plasma virions and CD4, lymphocytes in HIV-1 infection in vivo
16. HIV-1 dynamics in vivo: Virion clearance rate, infected cell-life span, and viral generation time
17. Fidelity of HIV-1 reverse transcriptase
18. The accuracy of reverse transcriptase from HIV-1 in vitro
19. Early penetration of the blood-brain-barrier by HIV
20. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients
21. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment
22. HIV-1 replication in plasma and cerebrospinal fluid
23. Analysis of HIV-1 load in blood, semen and saliva: Evidence for different viral compartments in a cross-sectional longitudinal study
24. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission
25. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission
26. Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients
27. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local virus replication
28. The hyperbolic function: A mathematical solution of the protein flux/CSF flow model for blood-CSF barrier function
29. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy
30. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
31. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome
32. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage
33. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources
34. Human immunodeficiency virus-associated dementia
35. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
36. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
37. The frequency of resistant mutant virus before antiviral therapy
38. Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infected patients prior to HAART and possible implications on HAART